The weight loss results from the current analyses are similarly aligned with clinical trials, however less pronounced as SURPASS-2 reported a mean weight change from baseline of 7.6 kg, 9.3 kg, and 11.2 kg for tirzepatide doses of 5 mg, 10 mg, and 15 mg, respectively and 5.7 kg with 1 mg semaglutide [21]
In the context of triple-negative immunotherapy for breast cancer, the combination of pyroptosis induction with immune checkpoint inhibitors has significant synergistic potential [62]
The medication affects areas of the brain responsible for appetite regulation, leading to reduced hunger and decreased calorie intake
A case study of dilated cardiomyopathy in a family of dogs was linked to lower myocardial L-carnitine levels compared to healthy control dogs
Villanger, G
Clinical studies comparing compounded and brand name GLP-1 medications show similar clinical goals and safety profiles